Breast Cancer
GeparOLA trial: Investigating the effectiveness of neoadjuvant Olaparib and Paclitaxel in treating early HER2-negative breast cancer with high homologous recombination deficiency (HRD).
In the phase II GeparOLA trial, Neoadjuvant #Olaparib plus paclitaxel was not superior to Paclitaxel-carboplatin regarding long-term outcomes in patients...
DESTINY-Breast02 trial: Trastuzumab deruxtecan after failure on TDM-1, An Update
In the phase 3 DESTINY-Breast02 trial, #Trastuzumab deruxtecan (T-DXd) improved the PFS and OS in patients with HER2-positive metastatic breast...
RxPONDER PRO sub-study: Impact of chemotherapy on cognitive functions in patients with early breast cancer.
In the #RxPONDER PRO sub-study presented by Dr. Irene Kang at the 2022 San Antonio Breast Cancer Symposium (SABCS) Annual...
STIC CTC trial: the use of circulating tumor cell (CTC) to guide the treatment in metastatic breast cancer.
In the phase 3 STIC CTC trial, overall survival (OS) was improved when circulating tumor cell (CTC) count was used...
monarchE trial: Abemaciclib in the adjuvant setting of HR-positive breast cancer
In the preplanned interim analysis of #monarchE trial, the addition of #abemaciclib to adjuvant endocrine therapy improved the invasive disease-free...
In a phase III Indian study, the addition of weekly carboplatin significantly improved overall survival and event-free survival when added to a taxane-anthracycline neoadjuvant chemotherapy regimen for patients with locally...
In the phase 2, PACE trial, the combination of #palbociclib plus fulvestrant did not improve significantly PFS compared with fulvestrant...
Neoadjuvant Carboplatin Shows Improved Survival in TNBC, Indian study
In a phase III Indian study, the addition of weekly carboplatin significantly improved overall survival and event-free survival when added...
RIGHT Choice trial - Ribociclib + Endocrine therapy PFS
-TN23-BC-.png)
The combination of ribociclib and endocrine therapy improved PFS in the first-line setting for premenopausal patients with aggressive ER-positive, HER2-negative...
SWOG S1207 trial - 1year adjuvant Everolimus to adjuvant Endocrine Therapy
In the phase 3 SWOG S1207 trial, the addition of 1 year of adjuvant Everolimus to adjuvant endocrine therapy failed...
CAPItello-291 trial - Capivasertib, oral AKT inhibitor, + Fulvestrant
In the phase 3 CAPItello-291 trial, presented at the SABCS, the addition of #capivasertib, an oral AKT inhibitor, to fulvestrant...
SERENA 2 trial - Camizestrant monotherapy, oral SERD, PFS
In the phase 2 SERENA 2 trial, presented at the SABCS, treatment with the oral #SERD, #camizestrant monotherapy, resulted in...
MITNEC-A1 study - 18F-sodium fluoride PET–CT vs 99mTc bone scintigraphy with SPECT
.png)
In multicenter, phase 3 #MITNEC-A1 study, 18F-sodium fluoride PET–CT was compared to 99mTc bone scintigraphy with SPECT in patients with...
SOPHIA trial
#Margetuximab failed to improve OS in patients with pretreated HER2- positive metastatic #breast_cancer in the final overall survival analysis of...
MITNEC-A1 study
In multicenter, phase 3 #MITNEC-A1 study, 18F-sodium fluoride PET–CT was compared to 99mTc bone scintigraphy with SPECT in patients with...
The effect of Behavoiral graded activities and psychological therapies in managing breast cancer symptoms
A systematic review and meta-analysis of 33 studies that included 4,330 #breast_cancer patients and was done to compare effectiveness of...
Breast cancer risk assessment model for women undergoing screening
An individualized breast cancer risk assessment model for women attending screening in BreastScreen Norway. The large retrospective cohort study included...
SINODAR-ONE trial
In a study published in the Annals of surgical oncology journal, further axillary lymph node dissection (ALND) failed to improve...
EMERALD trial
.png)
In a study published in the Journal of clinical oncology, Oral #SERD, #Elacestrant significantly improved PFS compared to standard of...
Surgery omission in early breast cancer
In a multicentre, single-arm, phase 2 trial conducted by MD Anderson Cancer Center, carefully selected early stage #TNBC or #HER2...
FDA safety recommendation
On Sept 8, 2022, the #FDA issued a safety communication to highlight reports of squamous cell carcinoma and various #lymphomas...
NRG Oncology/RTOG 1005 trial
The moderate hypofractionated radiotherapy course (3-weeks with concomitant boost) resulted in comparable safety and efficacy to the normal fractionation (4-6...
Mepitel Film to reduce skin radiotoxicity in breast cancer
A locally applied, silicone-based polyurethane film dressing (Mepitel Film) can reduce #radiation induced skin toxicities in #breast_cancer patients. According a...
BIG3-07/TROG 07.01 trial
#Radiation_therapy boost improved local control in DCIS of the breast with one or more risk factors as recently shown by...
GIM-2 trial
In the phase III, GIM-2 study that was presented by Del Mastro el al, #dose_dense chemotherapy significantly improved DFS and...
FDA approval of bevacizumab biosimilar
On September 28th 2022, the FDA has approved Celltrion’s #bevacizumab biosimilar (bevacizumab-adcd) in six types of cancers which are: metastatic...
DATA trial
In the phase III, DATA study that was presented by Tjan-Heijnen el al, #extended_adjuvant endocrine therapy failed to improve the...
TROPICS-2 trial
In the phase III, TROPICS-2 study presented by Hope Rugo el al, #Sacituzumab_govitecan (SG) significantly improved OS (median 14.4 vs...
DAWNA-2 trial
In the Chinese phase III, DAWNA-2 study presented by Xu el al, the addition of the CDK 4/6 inhibitor #Dalbiciclib...
MONARCH-3 trial
In the second interim analysis of the phase III MONARCH-3 study, that was presented by Dr Matthew Goetz adding #Abemaciclib...
KEYNOTE 355 trial
Adding #pembrolizumab to chemotherapy resulted in significantly longer overall survival among patients with previously untreated advanced #triple_negative_breast_cancer whose tumors expressed...
.png)
.png)
.png)
.png)
.png)